Difference between revisions of "Low-grade glioma, pediatric"
m |
|||
(18 intermediate revisions by 2 users not shown) | |||
Line 4: | Line 4: | ||
</div> | </div> | ||
{{#lst:Editorial board transclusions|peds-neuro}} | {{#lst:Editorial board transclusions|peds-neuro}} | ||
− | + | ''This page contains studies that are specific to pediatric populations. | |
*For the more general '''low-grade glioma''' category page, follow '''[[Low-grade_glioma|this link]]'''. | *For the more general '''low-grade glioma''' category page, follow '''[[Low-grade_glioma|this link]]'''. | ||
− | *For '''pediatric high-grade glioma (pHGG)''', follow '''[[High-grade glioma, pediatric|this link]]'''. | + | *For '''pediatric high-grade glioma (pHGG)''', follow '''[[High-grade glioma, pediatric|this link]]'''. |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 14: | Line 14: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
− | == | + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' |
− | *[https://www.nccn.org/ | + | ==NCCN== |
+ | *[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1509 NCCN Guidelines - Pediatric Central Nervous System Cancers] | ||
=Adjuvant therapy= | =Adjuvant therapy= | ||
==Carboplatin & Vincristine {{#subobject:056d2c|Regimen=1}}== | ==Carboplatin & Vincristine {{#subobject:056d2c|Regimen=1}}== | ||
Line 30: | Line 31: | ||
|- | |- | ||
|[https://doi.org/10.1200/JCO.1993.11.5.850 Packer et al. 1993] | |[https://doi.org/10.1200/JCO.1993.11.5.850 Packer et al. 1993] | ||
− | | | + | |Not reported |
| style="background-color:#91cf61" |Non-randomized | | style="background-color:#91cf61" |Non-randomized | ||
| style="background-color:#d3d3d3" | | | style="background-color:#d3d3d3" | | ||
Line 55: | Line 56: | ||
<div class="toccolours" style="background-color:#cbd5e7"> | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
− | *[[#Carboplatin_. | + | *[[#Carboplatin_.26_Vincristine_2|CV]] consolidation |
</div></div><br> | </div></div><br> | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 79: | Line 80: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Carboplatin (Paraplatin)]] 550 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | + | *[[Carboplatin (Paraplatin)]] as follows: |
+ | **Cycles 1 to 4: 550 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | ||
+ | **Cycles 5 to 7: 550 mg/m<sup>2</sup> IV over 60 minutes once on day 1 | ||
*[[Vincristine (Oncovin)]] as follows: | *[[Vincristine (Oncovin)]] as follows: | ||
**Cycles 1 to 4: 1.5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15 | **Cycles 1 to 4: 1.5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15 | ||
Line 87: | Line 90: | ||
<div class="toccolours" style="background-color:#cbd5e7"> | <div class="toccolours" style="background-color:#cbd5e7"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
− | *[[#Carboplatin_. | + | *[[#Carboplatin_.26_Vincristine_2|CV]] consolidation |
+ | </div></div> | ||
+ | |||
+ | ===References=== | ||
+ | # Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN, Phillips PC, Ryan J, Boyett JM, Geyer R, Finlay J. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993 May;11(5):850-6. [https://doi.org/10.1200/JCO.1993.11.5.850 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/8487049/ PubMed] | ||
+ | # '''COG A9952:''' Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, Vezina G, Wisoff JH, Pollack IF. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20;30(21):2641-7. Epub 2012 Jun 4. [https://doi.org/10.1200/JCO.2011.36.6054 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413276/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/22665535/ PubMed] [https://clinicaltrials.gov/study/NCT00002944 NCT00002944] | ||
+ | # '''SIOP-LGG 2004:''' Gnekow AK, Walker DA, Kandels D, Picton S, Perilongo G, Grill J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De Salvo GL; of the Low Grade Glioma Consortium and the participating centers. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - a final report. Eur J Cancer. 2017 Aug;81:206-225. Epub 2017 Jun 22. Erratum in: Eur J Cancer. 2017 Dec 13;:. [https://doi.org/10.1016/j.ejca.2017.04.019 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517338/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/28649001/ PubMed] EudraCT 2005-005377-29 | ||
+ | # '''LOGGIC/FIREFLY-2:''' [https://clinicaltrials.gov/study/NCT05566795 NCT05566795] | ||
+ | |||
+ | =Consolidation after adjuvant therapy= | ||
+ | ==Carboplatin & Vincristine {{#subobject:05jcn4|Regimen=1}}== | ||
+ | CV: '''<u>C</u>'''arboplatin & '''<u>V</u>'''incristine | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #1, 8 cycles {{#subobject:38uve6|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Dates of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413276/ Ater et al. 2012 (COG A9952)] | ||
+ | |1997-2005 | ||
+ | | style="background-color:#91cf61" |Non-randomized part of phase 3 RCT | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
+ | ====Preceding treatment==== | ||
+ | *Adjuvant [[#Carboplatin_.26_Vincristine|CV]] | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Carboplatin (Paraplatin)]] 175 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | ||
+ | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 8, 15 | ||
+ | '''42-day cycle for 8 cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #2, 10 cycles {{#subobject:3yrwe6|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Dates of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517338/ Gnekow et al. 2017 (SIOP-LCG 2004)] | ||
+ | |2004-2012 | ||
+ | | style="background-color:#91cf61" |Non-randomized part of phase 3 RCT | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
+ | ====Preceding treatment==== | ||
+ | *Adjuvant [[#Carboplatin_.26_Vincristine|CV]] | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Carboplatin (Paraplatin)]] 550 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15 | ||
+ | '''42-day cycle for 10 cycles''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #3, 12 cycles {{#subobject:38uv12|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Dates of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/JCO.1993.11.5.850 Packer et al. 1993] | ||
+ | |Not reported | ||
+ | | style="background-color:#91cf61" |Non-randomized | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
+ | ====Preceding treatment==== | ||
+ | *Adjuvant [[#Carboplatin_.26_Vincristine|CV]] | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Carboplatin (Paraplatin)]] 175 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22 | ||
+ | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 8, 15 | ||
+ | '''42-day cycle for 12 cycles''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN, Phillips PC, Ryan J, Boyett JM, Geyer R, Finlay J. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993 May;11(5):850-6. [https://doi.org/10.1200/JCO.1993.11.5.850 link to original article] ''' | + | # Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN, Phillips PC, Ryan J, Boyett JM, Geyer R, Finlay J. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993 May;11(5):850-6. [https://doi.org/10.1200/JCO.1993.11.5.850 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/8487049/ PubMed] |
− | # '''COG A9952:''' Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, Vezina G, Wisoff JH, Pollack IF. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20;30(21):2641-7. Epub 2012 Jun 4. [https://doi.org/10.1200/JCO.2011.36.6054 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413276/ link to PMC article] ''' | + | # '''COG A9952:''' Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, Vezina G, Wisoff JH, Pollack IF. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20;30(21):2641-7. Epub 2012 Jun 4. [https://doi.org/10.1200/JCO.2011.36.6054 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413276/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/22665535/ PubMed] [https://clinicaltrials.gov/study/NCT00002944 NCT00002944] |
− | # '''SIOP-LGG 2004:''' Gnekow AK, Walker DA, Kandels D, Picton S, Perilongo G, Grill J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De Salvo GL; of the Low Grade Glioma Consortium and the participating centers. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - a final report. Eur J Cancer. 2017 Aug;81:206-225. Epub 2017 Jun 22. Erratum in: Eur J Cancer. 2017 Dec 13;:. [https://doi.org/10.1016/j.ejca.2017.04.019 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517338/ link to PMC article] ''' | + | # '''SIOP-LGG 2004:''' Gnekow AK, Walker DA, Kandels D, Picton S, Perilongo G, Grill J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De Salvo GL; of the Low Grade Glioma Consortium and the participating centers. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - a final report. Eur J Cancer. 2017 Aug;81:206-225. Epub 2017 Jun 22. Erratum in: Eur J Cancer. 2017 Dec 13;:. [https://doi.org/10.1016/j.ejca.2017.04.019 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517338/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/28649001/ PubMed] |
+ | |||
=Recurrent or progressive, non-curative therapy= | =Recurrent or progressive, non-curative therapy= | ||
+ | ==Carboplatin & Vincristine {{#subobject:0jjd2c|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:cuhh41|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1056/nejmoa2303815 Bouffet et al. 2023 (TADPOLE)] | ||
+ | |2017-2021 | ||
+ | | style="background-color:#1a9851" |Randomized Phase 2 (C) | ||
+ | |[[#Dabrafenib_.26_Trametinib|Dabrafenib & Trametinib]] | ||
+ | | style="background-color:#d73027" |Inferior ORR | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#fdcdac"> | ||
+ | ====Biomarker eligibility criteria==== | ||
+ | *BRAF V600 mutation | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Carboplatin (Paraplatin)]] 175 mg/m<sup>2</sup> IV once per day on days 0, 7, 14, 21, 42, 49, 56, 63 | ||
+ | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 0, 7, 14, 21, 28, 35, 42, 49, 56, 63 | ||
+ | '''10-week course''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''TADPOLE:''' Bouffet E, Hansford JR, Garrè ML, Hara J, Plant-Fox A, Aerts I, Locatelli F, van der Lugt J, Papusha L, Sahm F, Tabori U, Cohen KJ, Packer RJ, Witt O, Sandalic L, Bento Pereira da Silva A, Russo M, Hargrave DR. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med. 2023 Sep 21;389(12):1108-1120. [https://doi.org/10.1056/nejmoa2303815 link to original article] '''does not contain dosing details in manuscript; refers to COG A9952''' [https://pubmed.ncbi.nlm.nih.gov/37733309/ PubMed] [https://clinicaltrials.gov/study/NCT02684058 NCT02684058] | ||
+ | |||
==Cisplatin & Etoposide (EP) {{#subobject:3a5f3f|Regimen=1}}== | ==Cisplatin & Etoposide (EP) {{#subobject:3a5f3f|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:55de5f|Variant=1}}=== | ===Regimen {{#subobject:55de5f|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | !style="width: | + | !style="width: 33%"|Study |
− | !style="width: | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://doi.org/10.1007/s11060-010-0136-6 Massimino et al. 2010] | |[https://doi.org/10.1007/s11060-010-0136-6 Massimino et al. 2010] | ||
+ | |2001-11 to 2007-12 | ||
|style="background-color:#91cf61"|Non-randomized | |style="background-color:#91cf61"|Non-randomized | ||
|- | |- | ||
Line 115: | Line 227: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Massimino M, Spreafico F, Riva D, Biassoni V, Poggi G, Solero C, Gandola L, Genitori L, Modena P, Simonetti F, Potepan P, Casanova M, Meazza C, Clerici CA, Catania S, Sardi I, Giangaspero F. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol. 2010 Oct;100(1):65-71. Epub 2010 Feb 12. [https://doi.org/10.1007/s11060-010-0136-6 link to original article] ''' | + | # Massimino M, Spreafico F, Riva D, Biassoni V, Poggi G, Solero C, Gandola L, Genitori L, Modena P, Simonetti F, Potepan P, Casanova M, Meazza C, Clerici CA, Catania S, Sardi I, Giangaspero F. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol. 2010 Oct;100(1):65-71. Epub 2010 Feb 12. [https://doi.org/10.1007/s11060-010-0136-6 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/20151174/ PubMed] |
+ | |||
==Dabrafenib & Trametinib {{#subobject:7d3694|Regimen=1}}== | ==Dabrafenib & Trametinib {{#subobject:7d3694|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 129: | Line 242: | ||
|2017-2021 | |2017-2021 | ||
| style="background-color:#1a9851" |Randomized Phase 2 (E-RT-switch-ooc) | | style="background-color:#1a9851" |Randomized Phase 2 (E-RT-switch-ooc) | ||
− | |[[#Carboplatin_. | + | |[[#Carboplatin_.26_Vincristine_3|Carboplatin & Vincristine]] |
| style="background-color:#1a9850" |Superior ORR (primary endpoint)<br>ORR: 47% vs 11%<br>(RR 4.31, 95% CI 1.7-11.2) | | style="background-color:#1a9850" |Superior ORR (primary endpoint)<br>ORR: 47% vs 11%<br>(RR 4.31, 95% CI 1.7-11.2) | ||
|- | |- | ||
Line 147: | Line 260: | ||
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
</div></div> | </div></div> | ||
+ | |||
===References=== | ===References=== | ||
− | #'''TADPOLE:''' Bouffet E, Hansford JR, Garrè ML, Hara J, Plant-Fox A, Aerts I, Locatelli F, van der Lugt J, Papusha L, Sahm F, Tabori U, Cohen KJ, Packer RJ, Witt O, Sandalic L, Bento Pereira da Silva A, Russo M, Hargrave DR. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med. 2023 Sep 21;389(12):1108-1120. [https://doi.org/10.1056/nejmoa2303815 link to original article] ''' | + | #'''TADPOLE:''' Bouffet E, Hansford JR, Garrè ML, Hara J, Plant-Fox A, Aerts I, Locatelli F, van der Lugt J, Papusha L, Sahm F, Tabori U, Cohen KJ, Packer RJ, Witt O, Sandalic L, Bento Pereira da Silva A, Russo M, Hargrave DR. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med. 2023 Sep 21;389(12):1108-1120. [https://doi.org/10.1056/nejmoa2303815 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/37733309/ PubMed] [https://clinicaltrials.gov/study/NCT02684058 NCT02684058] |
==Temozolomide monotherapy {{#subobject:7b66b|Regimen=1}}== | ==Temozolomide monotherapy {{#subobject:7b66b|Regimen=1}}== | ||
Line 187: | Line 301: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH; Children's Oncology Group. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. [https://doi.org/10.1002/cncr.22961 link to original article] ''' | + | # Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH; Children's Oncology Group. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. [https://doi.org/10.1002/cncr.22961 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/17705175/ PubMed] |
+ | |||
+ | ==Tovorafenib monotherapy {{#subobject:7toc23b|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:boc4rl|Variant=1}}=== | ||
+ | {| class="wikitable" style="color:white; background-color:#404040" | ||
+ | |<small>'''FDA-recommended dose'''</small> | ||
+ | |- | ||
+ | |} | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Dates of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://clinicaltrials.gov/study/NCT04775485 Awaiting publication (FIREFLY-1)] | ||
+ | |2021-2022 | ||
+ | |style="background-color:#91cf61"|Phase 2 (RT) | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#fdcdac"> | ||
+ | ====Biomarker eligibility criteria==== | ||
+ | *BRAF alteration | ||
+ | ====Prior treatment criteria==== | ||
+ | *At least one line of prior systemic therapy | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Targeted therapy==== | ||
+ | *[[Tovorafenib (Ojemda)]] 380 mg/m<sup>2</sup> (maximum dose of 600 mg) PO once on day 1 | ||
+ | '''7-day cycles''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''FIREFLY-1:''' [https://clinicaltrials.gov/study/NCT04775485 NCT04775485] | ||
+ | |||
[[Category:Low-grade glioma regimens]] | [[Category:Low-grade glioma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Low-grade gliomas]] | [[Category:Low-grade gliomas]] | ||
[[Category:Pediatric neurologic neoplasms]] | [[Category:Pediatric neurologic neoplasms]] |
Latest revision as of 23:49, 20 July 2024
Section editor | |
---|---|
Nicole M. Wood, DO University of Missouri Kansas City, MO, USA |
This page contains studies that are specific to pediatric populations.
- For the more general low-grade glioma category page, follow this link.
- For pediatric high-grade glioma (pHGG), follow this link.
7 regimens on this page
11 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
Adjuvant therapy
Carboplatin & Vincristine
CV: Carboplatin & Vincristine
VC: Vincristine & Carboplatin
Regimen variant #1, 175/1.5 (capped vincristine)
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Packer et al. 1993 | Not reported | Non-randomized | ||
Ater et al. 2012 (COG A9952) | 1997-2005 | Phase 3 (C) | TPCV | Did not meet co-primary endpoints of EFS/OS |
Note: The course begins on day 0.
Preceding treatment
Chemotherapy
- Carboplatin (Paraplatin) 175 mg/m2 IV once per day on days 0, 7, 14, 21, 42, 49, 56, 63
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 0, 7, 14, 21, 28, 35, 42, 49, 56, 63
10-week course
Subsequent treatment
- CV consolidation
Regimen variant #2, 550/1.5 (uncapped vincristine)
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Gnekow et al. 2017 (SIOP-LCG 2004) | 2004-2012 | Phase 3 (C) | VCE | Did not meet primary endpoint of PFS |
Preceding treatment
Chemotherapy
- Carboplatin (Paraplatin) as follows:
- Cycles 1 to 4: 550 mg/m2 IV over 60 minutes once on day 1
- Cycles 5 to 7: 550 mg/m2 IV over 60 minutes once on day 1
- Vincristine (Oncovin) as follows:
- Cycles 1 to 4: 1.5 mg/m2 IV once per day on days 1, 8, 15
- Cycles 5 to 7: 1.5 mg/m2 IV once on day 1
21-day cycle for 4 cycles, then 28-day cycle for 3 cycles
Subsequent treatment
- CV consolidation
References
- Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN, Phillips PC, Ryan J, Boyett JM, Geyer R, Finlay J. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993 May;11(5):850-6. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- COG A9952: Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, Vezina G, Wisoff JH, Pollack IF. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20;30(21):2641-7. Epub 2012 Jun 4. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00002944
- SIOP-LGG 2004: Gnekow AK, Walker DA, Kandels D, Picton S, Perilongo G, Grill J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De Salvo GL; of the Low Grade Glioma Consortium and the participating centers. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - a final report. Eur J Cancer. 2017 Aug;81:206-225. Epub 2017 Jun 22. Erratum in: Eur J Cancer. 2017 Dec 13;:. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed EudraCT 2005-005377-29
- LOGGIC/FIREFLY-2: NCT05566795
Consolidation after adjuvant therapy
Carboplatin & Vincristine
CV: Carboplatin & Vincristine
Regimen variant #1, 8 cycles
Study | Dates of enrollment | Evidence |
---|---|---|
Ater et al. 2012 (COG A9952) | 1997-2005 | Non-randomized part of phase 3 RCT |
Preceding treatment
- Adjuvant CV
Chemotherapy
- Carboplatin (Paraplatin) 175 mg/m2 IV once per day on days 1, 8, 15, 22
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 8, 15
42-day cycle for 8 cycles
Regimen variant #2, 10 cycles
Study | Dates of enrollment | Evidence |
---|---|---|
Gnekow et al. 2017 (SIOP-LCG 2004) | 2004-2012 | Non-randomized part of phase 3 RCT |
Preceding treatment
- Adjuvant CV
Chemotherapy
- Carboplatin (Paraplatin) 550 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1, 8, 15
42-day cycle for 10 cycles
Regimen variant #3, 12 cycles
Study | Dates of enrollment | Evidence |
---|---|---|
Packer et al. 1993 | Not reported | Non-randomized |
Preceding treatment
- Adjuvant CV
Chemotherapy
- Carboplatin (Paraplatin) 175 mg/m2 IV once per day on days 1, 8, 15, 22
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 8, 15
42-day cycle for 12 cycles
References
- Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN, Phillips PC, Ryan J, Boyett JM, Geyer R, Finlay J. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993 May;11(5):850-6. link to original article dosing details in manuscript have been reviewed by our editors PubMed
- COG A9952: Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, Vezina G, Wisoff JH, Pollack IF. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20;30(21):2641-7. Epub 2012 Jun 4. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT00002944
- SIOP-LGG 2004: Gnekow AK, Walker DA, Kandels D, Picton S, Perilongo G, Grill J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De Salvo GL; of the Low Grade Glioma Consortium and the participating centers. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - a final report. Eur J Cancer. 2017 Aug;81:206-225. Epub 2017 Jun 22. Erratum in: Eur J Cancer. 2017 Dec 13;:. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed
Recurrent or progressive, non-curative therapy
Carboplatin & Vincristine
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Bouffet et al. 2023 (TADPOLE) | 2017-2021 | Randomized Phase 2 (C) | Dabrafenib & Trametinib | Inferior ORR |
Biomarker eligibility criteria
- BRAF V600 mutation
Chemotherapy
- Carboplatin (Paraplatin) 175 mg/m2 IV once per day on days 0, 7, 14, 21, 42, 49, 56, 63
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 0, 7, 14, 21, 28, 35, 42, 49, 56, 63
10-week course
References
- TADPOLE: Bouffet E, Hansford JR, Garrè ML, Hara J, Plant-Fox A, Aerts I, Locatelli F, van der Lugt J, Papusha L, Sahm F, Tabori U, Cohen KJ, Packer RJ, Witt O, Sandalic L, Bento Pereira da Silva A, Russo M, Hargrave DR. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med. 2023 Sep 21;389(12):1108-1120. link to original article does not contain dosing details in manuscript; refers to COG A9952 PubMed NCT02684058
Cisplatin & Etoposide (EP)
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Massimino et al. 2010 | 2001-11 to 2007-12 | Non-randomized |
Note: In children less than 1 year old or less than 10 kg, "doses were adjusted to their weight"--reference does not say exactly how doses are adjusted.
Chemotherapy
- Cisplatin (Platinol) 25 mg/m2 IV over 2 hours once per day on days 1 to 3, given first
- Etoposide (Vepesid) 100 mg/m2 IV over 30 minutes once per day on days 1 to 3, given second
Supportive therapy
- Hydration for 2 hours before chemotherapy, and for 2 hours after chemotherapy
28-day cycle for 4 cycles, then 35-day cycle for 3 cycles, then 42-day cycle for 3 cycles
References
- Massimino M, Spreafico F, Riva D, Biassoni V, Poggi G, Solero C, Gandola L, Genitori L, Modena P, Simonetti F, Potepan P, Casanova M, Meazza C, Clerici CA, Catania S, Sardi I, Giangaspero F. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol. 2010 Oct;100(1):65-71. Epub 2010 Feb 12. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Dabrafenib & Trametinib
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Bouffet et al. 2023 (TADPOLE) | 2017-2021 | Randomized Phase 2 (E-RT-switch-ooc) | Carboplatin & Vincristine | Superior ORR (primary endpoint) ORR: 47% vs 11% (RR 4.31, 95% CI 1.7-11.2) |
Biomarker eligibility criteria
- BRAF V600 mutation
Targeted therapy
- Dabrafenib (Tafinlar) by the following age-based criteria:
- Less than 12 years old: 2.625 mg/kg PO twice per day
- 12 years or older: 2.25 mg/kg PO twice per day
- Trametinib (Mekinist) by the following age-based criteria:
- Less than 6 years old: 0.032 mg/kg PO once per day
- 6 years or older: 0.025 mg/kg PO once per day
Continued indefinitely
References
- TADPOLE: Bouffet E, Hansford JR, Garrè ML, Hara J, Plant-Fox A, Aerts I, Locatelli F, van der Lugt J, Papusha L, Sahm F, Tabori U, Cohen KJ, Packer RJ, Witt O, Sandalic L, Bento Pereira da Silva A, Russo M, Hargrave DR. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med. 2023 Sep 21;389(12):1108-1120. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02684058
Temozolomide monotherapy
Regimen variant #1
Study | Dates of enrollment | Evidence |
---|---|---|
Nicholson et al. 2007 | 1998-1999 | Non-randomized |
Note: This dosing is for patients who previously received craniospinal irradiation (CSI).
Chemotherapy
- Temozolomide (Temodar) 180 mg/m2 PO once per day on days 1 to 5
28-day cycle for 11 cycles
Regimen variant #2
Study | Dates of enrollment | Evidence |
---|---|---|
Nicholson et al. 2007 | 1998-1999 | Non-randomized |
Chemotherapy
- Temozolomide (Temodar) 200 mg/m2 PO once per day on days 1 to 5
28-day cycle for 11 cycles
References
- Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH; Children's Oncology Group. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Tovorafenib monotherapy
Regimen
FDA-recommended dose |
Study | Dates of enrollment | Evidence |
---|---|---|
Awaiting publication (FIREFLY-1) | 2021-2022 | Phase 2 (RT) |
Biomarker eligibility criteria
- BRAF alteration
Prior treatment criteria
- At least one line of prior systemic therapy
Targeted therapy
- Tovorafenib (Ojemda) 380 mg/m2 (maximum dose of 600 mg) PO once on day 1
7-day cycles
References
- FIREFLY-1: NCT04775485